Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005847 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005847: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00005847 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005847, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which treatment regimen is more effective in treating metastatic prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy with that of chemotherapy plus biological therapy in treating patients who have progressive or metastatic prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG paclitaxel
- BIOLOGICAL recombinant interferon alfa
- DRUG mitoxantrone hydrochloride
- DRUG estramustine phosphate sodium
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04-05 |
| Phase | Phase 2 |
What the finished NCT00005847 record still lists
NCT00005847 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which paclitaxel is the first listed.
NCT00005847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005847 about?
NCT00005847 is a clinical study titled "Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet kno...
What is the current status of trial NCT00005847?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-04-05.
What interventions are being tested in trial NCT00005847?
The interventions under investigation include: paclitaxel (DRUG), recombinant interferon alfa (BIOLOGICAL), mitoxantrone hydrochloride (DRUG), estramustine phosphate sodium (DRUG), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00005847?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI